Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma.

PURPOSE Different prognostic factors stratify patients with pancreatic adenocarcinoma. The purpose of this study was to determine whether preoperative CA19-9 levels can predict stage of disease or survival and whether a change in preoperative to postoperative CA19-9 or the postoperative CA19-9 predicts overall survival. PATIENTS AND METHODS Four hundred twenty-four consecutive patients with pancreatic adenocarcinoma underwent resection between January 1, 1985 and January 1, 2004. Of the patients with a bilirubin less than 2 mg/dL, 176 had preoperative CA19-9 values, and 111 had pre- and postoperative CA19-9 values. Survival was measured from the first postoperative CA19-9 level measured (median, 39 days) until death or last follow-up. A multivariate failure time model was fit using clinical, operative, pathologic, and adjuvant treatment characteristics, and a categorization was defined by the values and changes in CA19-9 before and after surgery. RESULTS Of the 176 patients, 128 (73%) had T3 lesions, and 99 (56%) had N1 disease; 138 patients (78%) underwent pancreaticoduodenectomy. Median preoperative CA19-9 levels were lower in N0 patients compared with patients with positive nodes (nine v 164 U/mL, respectively; nonparametric P = .06) and in T1/T2 patients versus T3 patients (41 v 162 U/mL, respectively; P = .03). Median follow-up time (n = 111) was 1.8 years (range, 1 to 12.9 years), with overall actuarial 1-, 3-, and 5-year survival rates of 70%, 36%, and 30%, respectively. Significant predictors of survival on multivariate analysis included a decrease in CA19-9 (P = .0005), negative lymph nodes (P = .001), lower T stage (P = .0008), and postoperative CA19-9 less than 200 U/mL (P = .0007). CONCLUSION In patients with pancreatic adenocarcinoma, preoperative CA19-9 correlates with stage of disease. Both a postoperative decrease in CA19-9 and a postoperative CA19-9 value of less than 200 U/mL are strong independent predictors of survival, even after adjusting for stage. CA19-9 levels should be included in a patient's perioperative care and should be considered for prognostic nomograms.

[1]  N. Scarmeas,et al.  CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer , 2005, Journal of Gastrointestinal Surgery.

[2]  B. Eisenberg,et al.  Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas , 1997, Annals of Surgical Oncology.

[3]  I. Meszoely,et al.  Undetectable Preoperative Levels of Serum CA 19-9 Correlate with Improved Survival for Patients with Resectable Pancreatic Adenocarcinoma , 2004, Annals of Surgical Oncology.

[4]  Diethelm Wallwiener,et al.  Authors' Disclosures of Potential Conflicts of Interest The authors indicated no potential conflicts of interest. , 2004 .

[5]  R. Bold,et al.  Utility of tumor markers in determining resectability of pancreatic cancer. , 2003, Archives of surgery.

[6]  N. Willich,et al.  CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. , 2003, Anticancer research.

[7]  V. Heinemann,et al.  CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin. , 1999, Anticancer Research.

[8]  J. Rhodes Usefulness of novel tumour markers. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  S. Nomoto,et al.  Clinical usefulness of CA-19-9 in pancreatic carcinoma. , 1998, Seminars in surgical oncology.

[10]  W. Schlosser,et al.  Prognostic value of CA 19-9 serum course in pancreatic cancer. , 1998, Hepato-gastroenterology.

[11]  H. Gogas,et al.  Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? , 1998, British Journal of Cancer.

[12]  H. Koprowski,et al.  Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. , 1983, Cancer research.

[13]  V. Zurawski,et al.  Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. , 1983, Clinical chemistry.

[14]  M. Herlyn,et al.  Specific antigen in serum of patients with colon carcinoma. , 1981, Science.

[15]  M. Herlyn,et al.  Colorectal carcinoma antigens detected by hybridoma antibodies , 1979, Somatic cell genetics.

[16]  D.,et al.  Regression Models and Life-Tables , 2022 .